论文部分内容阅读
目的探究拉米夫定治疗乙肝肝硬化伴脾亢患者的治疗效果与安全性。方法乙肝肝硬化伴脾亢患者200例,随机分为实验组和对照组,每组100例,其中实验组患者采取拉米夫定进行治疗,对照组患者采取常规治疗方法进行治疗,治疗时间为1年,1年后对患者的血清学、生化学、病毒学及肝脏的合成指标、部分组织学变化进行对比分析。结果经过1年的治疗,患者肝功能恢复情况、生化指标、HBV-DNA转阴率、HBeAg阴转率等情况均较治疗前好转,且实验组的治疗效果明显优于对照组,比较差异具有统计学意义(P<0.05)。结论乙肝肝硬化伴脾亢患者用拉米夫定进行治疗能够有效改善肝功能,且1年后治疗效果依旧明显,病毒复发率低,治疗效果和安全性较常规治疗高,值得在临床范围内大力推广。
Objective To investigate the efficacy and safety of lamivudine in the treatment of patients with hepatitis B cirrhosis complicated with hypersplenism. Methods 200 cases of hepatitis B cirrhosis with hypersplenism were randomly divided into experimental group and control group, 100 cases in each group, in which the experimental group was treated with lamivudine, while the control group was treated by conventional treatment, the treatment time was One year and one year later, the patients’ serology, biochemistry, virology, liver synthesis index and some histological changes were compared and analyzed. Results After one year of treatment, the recovery of liver function, biochemical indexes, HBV-DNA negative rate and HBeAg negative rate were all better than those before treatment, and the therapeutic effect of the experimental group was obviously better than that of the control group Statistical significance (P <0.05). Conclusion Hepatitis B cirrhosis with hypersplenism patients treated with lamivudine can effectively improve liver function, and the treatment effect is still obvious after 1 year, the virus recurrence rate is low, the treatment effect and safety are higher than the conventional treatment, it is worth in the clinical scope Promote.